Novartis Forecast, price target & analysts
Novartis Target price 2026 - Analyst rating & recommendation
Novartis Classifications & Recommendation:
Novartis Price Target
| Target Price | CHF111.66 |
| Price | CHF109.60 |
| Potential | 1.88% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target Novartis 2027 . The average Novartis target price is CHF111.66. This is 1.88% higher than the current stock price. The highest price target is CHF133.14 21.48% , the lowest is CHF88.88 18.91% . | |
| A rating was issued by 31 analysts: 14 Analysts recommend Novartis to buy, 13 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2027 of 1.88% . Most analysts recommend the Novartis stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
26 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF44.8b . This is 0.98% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF47.7b 7.49% , the lowest is CHF42.2b 4.85% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF41.0b | 10.85% |
|---|---|---|
| 2025 | CHF44.8b | 9.38% |
| 2026 | CHF46.0b | 2.69% |
| 2027 | CHF47.9b | 4.14% |
| 2028 | CHF50.5b | 5.33% |
| 2029 | CHF52.9b | 4.80% |
| 2030 | CHF54.9b | 3.80% |
| 2031 | CHF58.8b | 7.09% |
| 2032 | CHF57.9b | 1.55% |
22 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF18.7b . This is 24.61% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF23.0b 53.13% , the lowest is CHF14.5b 3.40% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF13.1b | 26.63% |
|---|---|---|
| 2025 | CHF18.7b | 42.77% |
| 2026 | CHF18.9b | 1.12% |
| 2027 | CHF19.9b | 5.35% |
| 2028 | CHF24.5b | 22.96% |
| 2029 | CHF26.2b | 6.84% |
| 2030 | CHF25.5b | 2.54% |
| 2031 | CHF22.5b | 11.70% |
| 2032 | CHF21.0b | 6.75% |
EBITDA Margin
| 2024 | 31.96% | 14.24% |
|---|---|---|
| 2025 | 41.71% | 30.52% |
| 2026 | 41.08% | 1.51% |
| 2027 | 41.55% | 1.14% |
| 2028 | 48.50% | 16.73% |
| 2029 | 49.44% | 1.94% |
| 2030 | 46.42% | 6.11% |
| 2031 | 38.28% | 17.54% |
| 2032 | 36.26% | 5.28% |
27 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF13.9b . This is 21.59% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF14.8b 30.18% , the lowest is CHF12.9b 13.27% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF9.5b | 19.59% |
|---|---|---|
| 2025 | CHF13.9b | 46.56% |
| 2026 | CHF14.2b | 2.32% |
| 2027 | CHF15.2b | 7.37% |
| 2028 | CHF17.0b | 11.46% |
| 2029 | CHF18.6b | 9.35% |
| 2030 | CHF18.9b | 1.98% |
Net Margin
| 2024 | 23.09% | 27.46% |
|---|---|---|
| 2025 | 30.93% | 33.97% |
| 2026 | 30.82% | 0.36% |
| 2027 | 31.78% | 3.11% |
| 2028 | 33.63% | 5.82% |
| 2029 | 35.09% | 4.34% |
| 2030 | 34.47% | 1.77% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
27 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF7.22 . This is 23.00% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF7.73 31.69% , the lowest is CHF6.73 14.65% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF4.65 | 17.26% |
|---|---|---|
| 2025 | CHF7.22 | 55.27% |
| 2026 | CHF7.39 | 2.35% |
| 2027 | CHF7.94 | 7.44% |
| 2028 | CHF8.85 | 11.46% |
| 2029 | CHF9.67 | 9.27% |
| 2030 | CHF9.86 | 1.96% |
| 2031 | CHF9.35 | 5.17% |
| 2032 | CHF8.05 | 13.90% |
P/E ratio
| Current | 18.67 | 50.93% |
|---|---|---|
| 2025 | 15.17 | 18.75% |
| 2026 | 14.83 | 2.24% |
| 2027 | 13.81 | 6.88% |
| 2028 | 12.39 | 10.28% |
| 2029 | 11.33 | 8.56% |
| 2030 | 11.11 | 1.94% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 5.05 and an P/S ratio of 4.66 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 5.10 | 0.59% |
|---|---|---|
| 2025 | 5.05 | 0.99% |
| 2026 | 4.92 | 2.62% |
| 2027 | 4.72 | 3.98% |
| 2028 | 4.48 | 5.06% |
| 2029 | 4.28 | 4.58% |
| 2030 | 4.12 | 3.66% |
| 2031 | 3.85 | 6.62% |
| 2032 | 3.91 | 1.58% |
P/S ratio
| Current | 4.70 | 0.16% |
|---|---|---|
| 2025 | 4.66 | 0.97% |
| 2026 | 4.53 | 2.62% |
| 2027 | 4.35 | 3.97% |
| 2028 | 4.13 | 5.06% |
| 2029 | 3.94 | 4.59% |
| 2030 | 3.80 | 3.66% |
| 2031 | 3.55 | 6.62% |
| 2032 | 3.60 | 1.57% |
Current Novartis Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Dec 11 2025 |
| INTESA SANPAOLO EQUITY RESEARCH |
Buy
➜
Buy
|
Unchanged | Dec 02 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Nov 24 2025 |
| ARGUS RESEARCH CORPORATION |
Hold
➜
Hold
|
Unchanged | Nov 24 2025 |
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Nov 24 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Nov 20 2025 |
| ROTHSCHILD & CO REDBURN |
Sell
➜
Sell
|
Unchanged | Nov 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Dec 11 2025 |
|
Unchanged
INTESA SANPAOLO EQUITY RESEARCH:
Buy
➜
Buy
|
Dec 02 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Nov 24 2025 |
|
Unchanged
ARGUS RESEARCH CORPORATION:
Hold
➜
Hold
|
Nov 24 2025 |
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Nov 24 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Nov 20 2025 |
|
Unchanged
ROTHSCHILD & CO REDBURN:
Sell
➜
Sell
|
Nov 05 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
